Physician profile

Nicolas Applyrs

Family Medicine · Fort Lauderdale, FL

NPI 1386208015

$415.03

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$132.02

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $124.85 2022
Gilead Sciences, INC. $88.32 2022
Astrazeneca Pharmaceuticals LP $86.94 2024 Airsupra
Hologic Sales and Service, LLC $26.04 2023 Thinprep 2000 Processor, Aptima
Allergan, INC. $20.56 2020
Novo Nordisk INC $19.12 2021
Medtronic, INC. $19.04 2023 Venaseal
Novartis Pharmaceuticals Corporation $16.60 2022
Baudax Bio INC. $13.56 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nicolas Applyrs

$415.03

in general payments reported 2019-2025

Years
2020-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/8800365/nicolas-applyrs

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.